On February 13, 2023, USANA Health Sciences, Inc. (the “Company” or “USANA”) filed a Current Report on Form 8-K (the “Initial 8-K) announcing that (i) its Board of Directors (the “Board”) appointed Jim Brown as the Company's Chief Executive Officer effective July 1, 2023 (the “Effective Date”), and (ii) Mr. Brown will succeed Kevin Guest, who will transition to Executive Chairman of the Company on the Effective Date. At the time of the Initial 8-K, the Compensation Committee of the Board (the “Compensation Committee”) had not determined the compensation arrangements for Mr. Brown or Mr. Guest in their new respective positions. In accordance with Instruction 2 to Item 5.02 of Form 8-K, the Company is filing this Amendment No.

1 to the Initial 8-K (“Amendment No. 1”) to provide information regarding the compensation arrangements for Mr. Brown and Mr. Guest in their new positions. These changes, were approved by the Compensation Committee on May 10, 2023 on the effective date of July 1, 2023.